myeloid cells

[Stem Cell Research & Therapy] The authors showed that donor differences in human MSC (hMSC) transcriptome were minor relative to the intrinsic differences in tissue-of-origin. hMSCs with different transcriptomic profiles showed potential differences in functional characteristics.

[Frontiers in Endocrinology] The authors differentiated iPSC from one donor into dendritic cells, macrophages, endothelial cells, and β-cells, and engineered T cell avatars from the same donor to provide an in vitro platform to study genetic influences on critical cellular interactions.

[Shoreline Biosciences] Dendreon Pharmaceuticals and Shoreline Biosciences, a biotechnology company developing allogeneic off-the-shelf, standardized, and targeted natural killer and macrophage cellular immunotherapies derived from iPSC for cancer, announced an alliance to advance the future of iPSC-derived cellular therapies.

[Molecular Pharmaceutics] Investigators used an in vitro peristaltic pump setup that mimiced pulsatile blood flow to determine if immune cells took up particles under constant fluidic flow.

[Journal of Experimental Medicine] Researchers observed that neutrophil DREAM repressed expression of A20, a negative regulator of NF-κB activity, and enhanced expression of pro-inflammatory molecules and phosphorylation of IκB kinase after TNF-α stimulation.

[Journal of Cellular Biochemistry] Researchers examined the role of Bcl2-associated athanogene (BAG3) to activate human fibroblasts in releasing cytokines capable of supporting tumor progression.